Mantle Cell Lymphoma with Central Nervous System Involvement Simulating Bilateral Subdural Hematomas

González-Bonet, Luis Germán; García‐Boyero, Raimundo; Gaona-Morales, John

doi:10.1016/j.wneu.2016.12.122

Cited by 6 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although our literature review focuses on immunocompetent patients with PCNSL, we recognize that SCNSL can also present like a subdural bleed in patients with a history of B-cell lymphoma. Gonzalez-Bonet et al described the case of a 71-year-old male who presented with a two-week history of neurological decline after a fall with head impact [14]. Although CT imaging was suspicious for bilateral SDH, the lesion was found to be recurrent mantle B-cell lymphoma on histopathology.…”

Section: Discussionmentioning

confidence: 99%

Primary Central Nervous System Lymphoma Presenting As Chronic Subdural Hematoma: Case Report and Review of the Literature

Semonche

Gómez

Kolcun

et al. 2020

Cureus

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) rarely manifests in immunocompetent patients. In such cases, these lesions may mimic more common intracranial bleeding or tumors. We present the case of an elderly patient who presented with a presumed chronic subdural hematoma (SDH); upon surgical intervention, an occult mass was discovered with no evidence of associated hematoma. Biopsy and immunohistochemistry demonstrated PCNSL. Literature review identified six other cases of PCNSL in immunocompetent adults that were initially suspected to be SDH but were finally diagnosed with PCNSL. Our literature review highlights the rarity these cases and the importance of distinguishing intracranial bleeds from PCNSL, as the latter can be treated with chemoradiation with good clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Central Nervous System Lymphoma Presenting As Chronic Subdural Hematoma: Case Report and Review of the Literature

Semonche

Gómez

Kolcun

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Indeed, the occurrence of mantle cell lymphoma in the CNS represents about 0.9% of all diagnosis of mantle cell lymphoma and 4% of recurrent cases [ 4 ].This type of localization is typically observed in high proliferating forms of MCL. CNS localization can involve many serious complications such as loss of consciousness [ 5 ]. There is no consensus on its treatment, and its survival is about 3–5 months after diagnosis [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma

Alsuliman¹,

Belghoul

Choufi³

2018

Case Reports in Hematology

View full text Add to dashboard Cite

Nowadays, mantle cell lymphoma is considered to have one of the worst prognostic profiles among lymphoid malignancies. Mantle cell lymphoma rarely affects the central nervous system (CNS) as it represents about 0.9% of diagnosis and 4% among recurrent cases. Here, we present the case of a 69-year-old male patient who was diagnosed with mantle cell lymphoma in 2006. The patient relapsed three times, without affecting the CNS, then was treated accordingly, and achieved complete remission three times. Four years after his last complete remission, upon receiving his last dose of treatment, the medical team noted a rapid worsening of the patient's neurological status followed by a deep coma state causing MCL neurological recurrence by exclusion diagnosis. The patient then received ibrutinib via a nasogastric tube at a dose of 560 mg daily. Two days after receiving his last dose of ibrutinib, the patient regained full consciousness, and 10 days later, he was discharged from the hospital. The patient achieved complete remission and showed no signs of neurological damages for 24 months following his ibrutinib treatment. We believe that the administration of ibrutinib through the nasogastric tube was a determinant factor in this patient's remission and survival.

show abstract

“…(10), mantijos ląstelių limfomos -4,1-5,6 proc. (11,12). Limfomos recidyvo CNS rizika didėja, jeigu diagnozuojama III ar IV stadijos liga, nustatomas išplitimas retroperitoniniuose limfiniuose mazguose arba kaulų čiulpuose, sėklidėse, krūtyje, sinusuose, ryklėje, tonzilėse, paravertebraliai, inkstuose, antinksčiuose, išmatuojama padidėjusi LDH koncentracija arba sumažėjęs albumino kiekis kraujo plazmoje (13).…”

unclassified

Intratekalinės Chemoterapijos Principai: Indikacijos, Medikamentai, Procedūra, Komplikacijos

Bašinskas¹,

Gerulytė²,

Rudžianskienė³

et al. 2019

Public Health

View full text Add to dashboard Cite

Intratekalinė chemoterapija – chemoterapijos vaistų suleidimas į stuburo smegenų kanalą, siekiant išgydyti onkologinę ligą arba išvengti jos recidyvo centrinėje nervų sistemoje. Dažniausiai šiam tikslui naudojami vaistai yra metotreksatas, citarabinas ir gliukokortikoidai. Jie gali būti naudojami atskirai arba kartu, t.y. taikoma triguba intratekalinė chemoterapija. Vaistai suleidžiami į subarachnoidinį tarpą atlikus juosmeninę punkciją. Po procedūros pacientą svarbu stebėti dėl nepageidaujamų chemoterapijos preparatų reiškinių (aseptinio meningito, cheminio arachnoidito, encefalopatijos, traukulių ir kt.) ir juosmeninės punkcijos komplikacijų (galvos ar nugaros skausmo, kraujavimo, infekcijos ir kt.).

show abstract

Mantle Cell Lymphoma with Central Nervous System Involvement Simulating Bilateral Subdural Hematomas

Cited by 6 publications

References 7 publications

Primary Central Nervous System Lymphoma Presenting As Chronic Subdural Hematoma: Case Report and Review of the Literature

Primary Central Nervous System Lymphoma Presenting As Chronic Subdural Hematoma: Case Report and Review of the Literature

Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma

Intratekalinės Chemoterapijos Principai: Indikacijos, Medikamentai, Procedūra, Komplikacijos

Contact Info

Product

Resources

About